Limits...
A randomized controlled study on the efficacy of a novel combination vaccine against enzootic pneumonia ( Mycoplasma hyopneumoniae ) and porcine Circovirus type 2 (PCV2) in the presence of strong maternally derived PCV2 immunity in pigs

View Article: PubMed Central - PubMed

ABSTRACT

Background: Mycoplasma hyopneumoniae (M. hyo) and Porcine Circovirus Type 2 (PCV2) are major pathogens that cause significant health problems in swine worldwide. Maternal derived immunity (MDI) has been suggested as a significant immediate defence factor for newborn piglets and may interfere with piglet’s vaccination-induced immunity. The study aimed to assess the efficacy of a novel combination vaccine (consisting of PCV2 subunits and inactivated M. hyo strain J), against PCV2 and M. hyo natural infection [Porcilis® PCV M Hyo (MSD Animal Health, Boxmeer, the Netherlands)], in the presence of strong maternally derived PCV2 immunity (antibody titre averaged 11.08 log2), under field conditions. The study was performed according to a controlled, randomized and blinded design in a Greek swine unit with Enzootic Pneumonia (EP) and subclinical PCV2 infection. In total, 600 healthy three-week-old suckling piglets were allocated randomly, either to treatment (vaccinated with the test product) or control group (injected with sterile buffered saline).

Results: Vaccination significantly reduced the severity of lung lesions at slaughter (lesions of cranio-ventral pulmonary consolidation) (P < 0.001). The overall mean lung lesion score (LLS) was 9.6 in the vaccinated group and 12.2 in controls. The level of PCV2 viraemia was significantly reduced in vaccinated pigs. Furthermore, 25 g higher average daily weight gain (ADWG) was observed during the finishing phase (P < 0.001) and 18 g greater ADWG overall (P < 0.001).

Conclusions: Results of LLS, PCV2 viremia and ADWG support the test product’s efficacy in the face of strong maternally derived PCV2 immunity.

No MeSH data available.


Mean log10 DNA copies PCV2 /per μl DNA extract, by vaccination group and weeks post-vaccination. Presented data refer only to the period when results were above the detection limits
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC5384188&req=5

Fig2: Mean log10 DNA copies PCV2 /per μl DNA extract, by vaccination group and weeks post-vaccination. Presented data refer only to the period when results were above the detection limits

Mentions: A total of 101 samples were tested by qPCR for PCV2 viral DNA. The mean viral load was significantly (Rank Sum test: P = 0.0004) lower in the vaccinated pigs than the controls. The results, expressed as the mean log10 DNA copies per μl DNA extract, are summarised in Fig. 2. Presented data refer only to the period when results were above the detection limits.Fig. 2


A randomized controlled study on the efficacy of a novel combination vaccine against enzootic pneumonia ( Mycoplasma hyopneumoniae ) and porcine Circovirus type 2 (PCV2) in the presence of strong maternally derived PCV2 immunity in pigs
Mean log10 DNA copies PCV2 /per μl DNA extract, by vaccination group and weeks post-vaccination. Presented data refer only to the period when results were above the detection limits
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC5384188&req=5

Fig2: Mean log10 DNA copies PCV2 /per μl DNA extract, by vaccination group and weeks post-vaccination. Presented data refer only to the period when results were above the detection limits
Mentions: A total of 101 samples were tested by qPCR for PCV2 viral DNA. The mean viral load was significantly (Rank Sum test: P = 0.0004) lower in the vaccinated pigs than the controls. The results, expressed as the mean log10 DNA copies per μl DNA extract, are summarised in Fig. 2. Presented data refer only to the period when results were above the detection limits.Fig. 2

View Article: PubMed Central - PubMed

ABSTRACT

Background: Mycoplasma hyopneumoniae (M. hyo) and Porcine Circovirus Type 2 (PCV2) are major pathogens that cause significant health problems in swine worldwide. Maternal derived immunity (MDI) has been suggested as a significant immediate defence factor for newborn piglets and may interfere with piglet’s vaccination-induced immunity. The study aimed to assess the efficacy of a novel combination vaccine (consisting of PCV2 subunits and inactivated M. hyo strain J), against PCV2 and M. hyo natural infection [Porcilis® PCV M Hyo (MSD Animal Health, Boxmeer, the Netherlands)], in the presence of strong maternally derived PCV2 immunity (antibody titre averaged 11.08 log2), under field conditions. The study was performed according to a controlled, randomized and blinded design in a Greek swine unit with Enzootic Pneumonia (EP) and subclinical PCV2 infection. In total, 600 healthy three-week-old suckling piglets were allocated randomly, either to treatment (vaccinated with the test product) or control group (injected with sterile buffered saline).

Results: Vaccination significantly reduced the severity of lung lesions at slaughter (lesions of cranio-ventral pulmonary consolidation) (P < 0.001). The overall mean lung lesion score (LLS) was 9.6 in the vaccinated group and 12.2 in controls. The level of PCV2 viraemia was significantly reduced in vaccinated pigs. Furthermore, 25 g higher average daily weight gain (ADWG) was observed during the finishing phase (P < 0.001) and 18 g greater ADWG overall (P < 0.001).

Conclusions: Results of LLS, PCV2 viremia and ADWG support the test product’s efficacy in the face of strong maternally derived PCV2 immunity.

No MeSH data available.